CAJ | 학술논문

以沪深两市2009-2012年医药生物类上市公司为样本，实证分析医药生物类产业的研发弹性和技术效率。研究发现：无论采用可变规模报酬还是固定规模报酬模型，医药生物类企业的研发支出对企业产值均有显著正向影响，研发弹性在0.10-0.20左右。然后运用随机前沿分析方法考察企业的技术效率和影响因素，发现医药生物类企业的平均技术效率在0.75左右，还有很大的提升空间。公司成立年限越长、国有股权比例越高，越有助于提升企业效率，处于我国中部地区以及资产负债率较高的公司，效率会受到负面影响。
이호심량시2009-2012년의약생물류상시공사위양본，실증분석의약생물류산업적연발탄성화기술효솔。연구발현：무론채용가변규모보수환시고정규모보수모형，의약생물류기업적연발지출대기업산치균유현저정향영향，연발탄성재0.10-0.20좌우。연후운용수궤전연분석방법고찰기업적기술효솔화영향인소，발현의약생물류기업적평균기술효솔재0.75좌우，환유흔대적제승공간。공사성립년한월장、국유고권비례월고，월유조우제승기업효솔，처우아국중부지구이급자산부채솔교고적공사，효솔회수도부면영향。
This paper analyzes R&D elasticity and technical efficiency in biomedical industry by using listed company in Shanghai and Shenzhen stock markets in the years of 2009-201 2 as samples.The study finds:regardless of the varia-ble returns to scale or constant returns to scale model,R&D expenditure of biological medicine enterprise has a signifi-cant positive effect on the basic sales of enterprises with R&D elasticity being around 0.1 0-0.20.Then,technical efficiency and its effecting factors are investigated by using Stochastic Frontier Approach.It is found that the average technical efficiency of biological medicine enterprises is about 0.75,hence there is still much room for improvement of efficiency.The longer enterprises are founded,the higher the proportion of state-owned shares of enterprises is,which is more beneficial to improve enterprise efficiency.Those enterprises which are located in the central region of China or with high asset liability ratio will be adversely affected on efficiency.